Alimera Sciences and Horus Pharma have expanded a distribution agreement to allow Horus to introduce Iluvien for diabetic macular edema and noninfectious posterior uveitis in the Benelux countries of Belgium, the Netherlands and Luxembourg, according to a press release.
Horus previously launched Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg) for the treatment of DME in France. Over the next 12 to 18 months, it will now apply for reimbursement in Belgium, the Netherlands and Luxembourg for both indications.
“We have enjoyed a productive and successful relationship with Horus Pharma, as they have obtained reimbursement for Iluvien in France and are executing an impressive launch in that territory,” Rick Eiswirth, president and CEO of Alimera, said in the release. “For those reasons, we made the decision to expand our relationship to include the Benelux countries where Horus also has considerable experience and reach. We look forward to potentially adding these three more countries to the list of anticipated Iluvien launches, as we continue to execute on our global commercial expansion strategy.”